Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Pieris Pharmaceuticals, Inc.

Anticalin proteins are artificial proteins that are able to bind to antigens, either to proteins or to small molecules. They are not structurally related to antibodies, which makes them a type of antibody mimetic. Instead, they are derived from human lipocalins which are a family of naturally binding proteins. Anticalin proteins are being used in lieu of monoclonal antibodies, but are about eight times smaller with a size of about 180 amino acids and a mass of about 20 kDa.

The Anticalin technology is exclusively commercialized by Pieris Pharmaceuticals in Freising, Germany. Anticalin is a registered trademark of Pieris.

Anticalin proteins have better tissue penetration than antibodies and are stable at temperatures up to 70 °C. Unlike antibodies, they can be produced in bacterial cells like E. coli in large amounts.

While antibodies can only be directed at macromolecules such as proteins and at small molecules (haptens) only if bound to macromolecules, Anticalin proteins are able to selectively bind to small molecules as well.

They were mainly developed at the Technical University of Munich and are currently used as research tools. Diagnostic and therapeutic applications, including the use for targeted drug delivery, are being aimed at. The underlying technology was nominated for the German Future Prize in 2004.

Characteristic for Anticalin proteins is their barrel structure formed by eight antiparallel β-strands pairwise connected by loops and an attached α-helix. The main structure of Anticalin proteins is identical to wild type lipocalins. Conformational deviations are primarily located in the four loops reaching in the ligand binding site. Mutagenesis of amino acids at the binding site allows for changing the affinity and selectivity.

Investment goal date:
Dividends reinvested
Pieris Pharmaceuticals, Inc. PIRS report
Period
Date
Adjusted Actuals EPS
GAAP EPS
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BlackRock Fund Advisors
70132
BlackRock Inc.
89592
BVF INC/IL
1917033
Creative Planning
60000
DAFNA Capital Management LLC
53525
DEUTSCHE BANK AG\
65337
EAM Investors, LLC
182737
GEODE CAPITAL MANAGEMENT, LLC
26244
Lombard Odier Asset Management (USA) Corp
2500000
MORGAN STANLEY
191917
ORBIMED ADVISORS LLC
7259620
RENAISSANCE TECHNOLOGIES LLC
254400
SPHERA FUNDS MANAGEMENT LTD.
1000000
Tekla Capital Management LLC
3940084
TFS CAPITAL LLC
32689
Major Shareholders
Name Relationship
Total Shares
Holding stocks